High expression of DNA topoisomerase IIalpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients

Eur J Cancer. 2002 Jul;38(10):1343-7. doi: 10.1016/s0959-8049(02)00065-5.

Abstract

Assessment of tumour cell proliferation in glioblastoma (GB) has been a topic of considerable research interest over the past decade. However, the correlation of tumour proliferation and patient outcome has yielded controversial results. In this study, we examined immunohistochemically, using paraffin-embedded tissue, the expression of the proliferation-related markers DNA topoisomerase IIalpha (TIIalpha) and Ki-67 antigen in a cohort of 114 GB patients treated consecutively with surgery and radiochemotherapy, and correlated the expression with patient outcome. The TIIalpha labelling index (LI) ranged between 5.2 and 87.2% (median: 25.6%). Survival analysis disclosed an association between high TIIalpha expression levels and prolonged survival (P=0.040, log-rank test). TIIalpha expression correlates closely with Ki-67 labelling index (R=0.927, P<0.001), which itself is predictive of patient survival (P=0.044). However, in multivariate analysis, only the Karnofsky performance status remained predictive of patient survival. We conclude that high expression of TIIalpha and Ki-67 appears to be associated with a prolonged survival in our cohort of GB patients.

MeSH terms

  • Adult
  • Aged
  • Brain Neoplasms / mortality*
  • Brain Neoplasms / therapy*
  • Cell Division
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • DNA Topoisomerases, Type II / metabolism*
  • Glioblastoma / mortality*
  • Glioblastoma / therapy*
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen / metabolism*
  • Middle Aged
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome

Substances

  • Ki-67 Antigen
  • DNA Topoisomerases, Type II